Antikor News Items

  1. Antikor Biopharma and Essex Bio-Technology Forge Strategic Alliance in FDC for Cancer Treatment
  2. Antikor takes aim at solid tumours with antibody-fragment conjugates
  3. Superior Toxicology Data from Antikor’s FDC Platform
  4. February 2017: Antikor is seeking to recruit top protein scientists
  5. Antikor awarded an Innovate-UK Early Stage award December 2016
  6. Breakthrough Achieved by Antikor Biopharma with Fragment-Drug Conjugates!
  7. Antikor invited to present at BioTrinity, April 2016
  8. Antikor CSO/COO attending the 6th World ADC Summit, Berlin, 8-10th February 2016
  9. Antikor attending Biotech & Money, London 2-3 February 2016
  10. Antikor attending Genesis 2015, London, 10th December
  11. Antikor invited to ‘Accessing US Capital In Life Sciences’, 1st December 2015
  12. Antikor selected to present at OBN CEO & Investor Forum, London, 24th November 2015
  13. Antikor invited to the World ADC Mastermind meeting in Cambridge, UK, 2nd September 2015
  14. Antikor invited to Amgen Partner Symposium Programme, 21 July 2015
  15. Antikor team publish review article on Emerging formats for next-generation antibody drug conjugates
  16. Antikor moves into new premises at Stevenage BioScience Catalyst